Clustering patterns of metabolic syndrome: A cross-sectional study in children and adolescents in Kyiv

Maiia H. Aliusef*, Ganna V. Gnyloskurenko, Alina V. Churylina and Inga O. Mityuryayeva

Department of Pediatrics, Bogomolets National Medical University, Kyiv, Ukraine

Objective: The aim: to identify subgroups by cluster analysis according parameters: original homeostatic model of insulin resistance (HOMA-1 IR), updated computer model of insulin resistance (HOMA-2 IR), β-cell function (%B) and insulin sensitivity (%S) for the prognosis of different variants of metabolic syndrome in children for more individualized treatment selection.

Patients and methods: The observational cross-sectional study on 75 children aged from 10 to 17 with metabolic syndrome according to the International Diabetes Federation criteria was conducted at the Cardiology Department of Children’s Clinical Hospital No.6 in Kyiv. HOMA-1 IR was calculated as follows: fasting insulin (µIU/ml) × fasting glucose (mmol/L)/22.5. HOMA-2 IR with %B and %S were calculated according to the computer model in [http://www.dtu.ox.ac.uk]. All biochemical analysis were carried out using Cobas 6000 analyzer and Roche Diagnostics (Switzerland). The statistical analysis was performed using STATISTICA 7.0 and Easy R. The hierarchical method Ward was used for cluster analysis according the parameters: HOMA-1 IR, HOMA-2 IR, %B and %S.

Results: Four clusters were identified from the dendrogram, which could predict four variants in the course of metabolic syndrome such that children in cluster 1 would have the worst values of the studied parameters and those in cluster 4 – the best. It was found that HOMA-1 IR was much higher in cluster 1 (6.32 ± 0.66) than in cluster 4 (2.19 ± 0.13). HOMA-2 IR was also much higher in cluster 1 (3.80 ± 0.34) than in cluster 4 (1.31 ± 0.06). By the analysis of variance using Scheffe’s multiple comparison method, a statistically significant difference was obtained between the laboratory parameters among the subgroups: HOMA-1 IR (p < 0.001), glucose (p < 0.001), insulin (p < 0.001), HOMA-2 IR (p < 0.001), %B (p < 0.001), %S (p < 0.001), TG (p = 0.005) and VLDL-C (p = 0.002).

Conclusions: A cluster analysis revealed that the first two subgroups of children had the worst insulin resistance and lipid profile parameters. It was found positive correlation between HOMA-1 IR, HOMA-2 IR, %B and %S with lipid metabolism parameters TG and VLDL-C and negative correlation between %B and HDL-C in children with metabolic syndrome (MetS). The risk of getting a high TG result in the blood analysis in children with MetS was significantly dependent with the HOMA-2 IR >2.26.

Keywords: cluster analysis, insulin resistance, insulin-secreting cells, metabolic syndrome, waist circumference
Introduction

The prevalence of metabolic syndrome in children varies widely according to different sources (1) and various diagnostic methods (2) This is due to not only the differences between nations and races, but also to lack of a unified diagnostic consensus in the pediatric population. Metabolic syndrome (MetS) represents a combination of multiple disorders including central or abdominal obesity, elevated blood pressure, dyslipidemia, type 2 diabetes mellitus or impaired glucose tolerance. According to the guidelines established by the International Diabetes Federation (IDF), MetS is diagnosed in children from the age of 10 years with the following criteria: abdominal obesity plus any two of four factors including high blood pressure, high triglyceride, low high-density lipoprotein cholesterol, high fasting plasma glucose (3).

The definition assumes that MetS is heterogeneous disease and one individual may have abdominal obesity, low HDL-C and high fasting plasma glucose, while another one has abdominal obesity, high blood pressure and high TG. Therefore, it is important to cluster patients based on one of the etiological mechanisms of the disease. One of the main long-established pathogenetic underpinnings for the development of the MetS is insulin resistance (IR) (4, 5). Many methods to measure IR have been published in the past. The most commonly used is the homeostatic model of insulin resistance (HOMA-IR), which is based on fasting insulin and glucose values. The original HOMA-1 IR model was described in 1985. Reduced β-cell function was modeled by changing the β-cell response concentration of plasma glucose. An updated HOMA (HOMA-2 IR) is the computer model in 1996 was calibrated to obtain β-cell function (%B) and insulin sensitivity (%S), given that a level of 100% is normal and IR of 1 (6). HOMA2-IR model has nonlinear solutions and these should be used compared with the HOMA1-IR minimal model. Also, HOMA2-IR model accounts for variations in hepatic and peripheral glucose tolerance and reduced peripheral glucose uptake stimulated by glucose. Previously, it was thought that insulin resistance causes an increase in plasma glucose levels, which contribute to the need for pancreatic insulin-secreting cells (β-cells) to produce and secrete more insulin. Chronic exposure to elevated glucose leads to β-cell dysfunction and cell death causing diabetes (7).

However, recently the theory that insulin resistance precedes beta cell dysfunction has been challenged and it is believed that beta cell hyperfunction leads subsequently to IR (8).

Therefore, appreciable destruction of β-cell, may occur often before the impaired glucose tolerance or persistent elevation of fasting glucose. It is also known that excessive cholesterol accumulation in β-cells can cause lipotoxicity and reduce insulin secretion, causing a reduction in the number of β-cells (9). Early studies have shown that people with hyperglycaemia have a more severely impaired lipid profile. Studies demonstrate that LDL-C inhibits glucose-stimulated insulin secretion and β-cell proliferation via LDL receptor mechanisms. Also, high levels of LDL-C (>6 mmol/L) cause β-cell apoptosis (10). Given the pathogenetic links between the processes outlined above, we suggested that beta cell activity and insulin sensitivity may be prognostic criteria for severity of the MetS. Therefore, the aim of our study was to identify subgroups of children with metabolic syndrome based on these indicators.

Materials and methods

The observational cross-sectional study on 75 children aged 10–17 with metabolic syndrome (MetS) was conducted at the Cardiology Department of Children’s Clinical Hospital No.6 in Kyiv. The sample size was calculated using the the package G*Power 3.1.9.7 (11). under the assumption of odds ratio =5 with frequency of qualitative characteristics ~0.5 (50%) and a critical significance level of 0.05 and power ~0.8. Calculation for quantitative characteristics was done assuming odds ratio =5 with a change of 0.5σ with a critical significance level of 0.05, power ~0.8. Inclusion criteria: all children who came to the clinic with the complaint of being overweight and who were diagnosed with MetS based on the IDF criteria: which include abdominal obesity plus two or more factors including blood pressure ≥130/85 mmHg, triglyceride level ≥1.7 mmol/L, high-density lipoprotein cholesterol <1.03 mmol/L, fasting plasma glucose ≥5.6 mmol/L. Exclusion criteria: patients with metabolic syndrome, associated with genetic syndromes. All anthropometric measurements were performed immediately upon the patient’s admission to the department. Body mass index and waist circumference according to growth charts were determined at all children (WC). BMI was assessed according to WHO growth charts. Abdominal obesity was established by measuring the WC ≥90 percentile for age and sex-specific. As there are no national WC charts, it was used the British references in adolescents as they reflect the patterns of WC in Caucasian children (12). 24-h ambulatory blood pressure monitoring was performed using ABM-04 («Meditech», Hungary) (13, 14). There were determined the parameters of the lipid profile which include total cholesterol (TC), triglycerides (TG), high-density lipoproteins (HDL-C), low-density lipoproteins (LDL-C), very low density lipoproteins (VLDL-C), atherogenic coefficient (AC). HOMA-1 IR was calculated using the formula: fasting insulin (μIU/ml) × fasting glucose (mmol/L)/22.5. HOMA-2 IR with beta-cell function (%B) and insulin sensitivity (%S) were calculated according to the computer model in [http://www.dtu.ox.ac.uk]. All
biochemical analysis were carried out by enzymatic colorimetric method of Cobas 6000, Roche Diagnostics (Switzerland) analyzer and test system. No patient was excluded at the end of the study. The hierarchical method Ward was performed for cluster analysis using the statistical package STATISTICA 7.0, which aim to minimize the main
variation within groups based on Euclidean distances. A non-parametric Spearman rank correlation test was used for the correlation analysis. The critical level of significance was estimated to be equal to or less than 0.05. In order to predict the binary initial variable under the influence of the factor variables, a logistic regression model was used. ROC-curve analysis was used to assess the quality of the logistic regression model. The statistical analysis was performed using EZR (Easy R) version 1.54 (December 24, 2020).

There may be some possible limitations in this study. This research is a pilot study and it is limited to the city of Kyiv. Also, the IDF classification limits the diagnosis of MetS to children from the age of 10 years, so the results of this article cannot be extrapolated to younger children. For children from 2 to 11 years, the IDEFICS classification should be used to diagnose MetS (15).

**Results**

The sample consisted of more males −60% (n = 60) than females −20% (n = 15) with a median of age of 15 years [interquartile range (IQR) 14–16]. Median BMI was of 28.73 kg/m² (IQR 26.85–31.74). Median WC − 91.5 cm (IQR 87.00–96.00). Median HOMA-1 IR was significantly higher −3.65 (IQR 2.75–5.96) than median HOMA-2 IR − 2.26 (IQR 1.64–3.46), p < 0.001 (Figure 1).

Median %B − 198.95 (IQR 142.35–253.65), median %S − 44.7 (IQR 29.05–61.4).

There was no significant difference between the median BMI of boys (28.71 ± 0.59), and girls (30.43 ± 1.47), p = 0.344. The WC was significantly higher in boys (92 ± 1.79) compared to girls (86 ± 1.52). HOMA-1 IR did not differ

![Figure 3](https://example.com/figure3.png)

**FIGURE 3**
Correlation field in coordinates: TG (X axis) and %B (Y axis). Spearman’s rank correlation coefficient 0.53 p.value = 0.000105.
between the groups: 3.54 ± 0.37 and 5.99 ± 0.96 respectively, \( p = 0.085 \). HOMA-2 IR had a gender difference with score for males –2.17 ± 0.19 and females –3.38 ± 0.502, \( p = 0.049 \). Glucose levels did not differ between genders –4.76 ± 0.09 and 4.99 ± 0.18, \( p = 0.269 \). The median insulin in boys (17.5 ± 1.702) was significantly lower than girls (27 ± 4.56), \( p = 0.045 \). Accordingly, %S showed higher values in boys (46.05 ± 3.53) than girls (29.6 ± 6.87) with \( p = 0.049 \). The median %B did not differ significantly between the males – 186.3 ± 13.22 and females – 224.1 ± 36.51 with \( p = 0.206 \).

In order to assess the relationship between the parameters of insulin resistance and lipid metabolism, a correlation analysis was performed. The results of the study are summarized in the heat map (Figure 2). The positive correlations were found between TG and HOMA-1 IR \( (r = 0.39) \), HOMA-2 IR \( (r = 0.47) \) and %B \( (r = 0.53) \) and negative correlation between TG and %S \( (r = -0.47) \), \( p < 0.05 \). VLDL-C was positively correlated with HOMA-1 IR \( (r = 0.34) \), HOMA-2 IR \( (r = 0.41) \) and %B \( (r = 0.64) \) and negatively with %S \( (r = -0.41) \). The negative correlation was observed between HDL-C and %B with \( r = 0.33 \) (\( p < 0.05 \)). The positive correlation was found between AC and %B \( (r = 0.35) \), \( p < 0.05 \).

The Figures 3, 4 show the correlation field of a pair of indices, where a correlation of medium strength was detected (Figures 3, 4).

Since the correlation analysis only answers the question of the presence of the relationship between the parameters, but not the cause-and-effect relationship, It was conducted a logistic regression model, where \( Y \) is a binary initial sign of the influence of factor variables: \( X_1, X_2,...,X_m \). Hence, for

---

**FIGURE 4**

Correlation field in coordinates: VLDL-C (X axis) and %B (Y axis). Spearman’s rank correlation coefficient 0.641, \( p \text{ value} = 0.0000257 \).
HOMA-2 IR there are no stabilized reference values, we suggested HOMA-2 IR ≤ 2.26 as the normal range and >2.26 as high. The relationship between normal and high ranges HOMA-2 IR (Y) with age (X1) and beta cell function (X2) was analysed. A two-factor model revealed a relationship between HOMA-2 IR and beta cell function [OR = 1.020 (95% CI 1.010–1.040) \( p = 0.0000588 \)] and age [OR = 0.663 (95%CI 0.463–0.951) \( p = 0.256 \)]. The area under the ROC (receiver operating characteristics) curve, AUC = 0.876 (95%CI 0.794–0.957), is significantly \( (p < 0.05) \) greater than 0.5, indicating the adequacy of the constructed model. The quality of the model was assessed as "very good" (Figure 5).

A five-factor model reveals the dependence of HOMA-2 IR (Y) on age (X1) and metabolic syndrome criteria (X2, X3, X4) the area under the ROC curve AUC = 0.836 (95% CI 0.717–0.956) is significantly \( (p < 0.05) \) greater than 0.5. To select a minimum set of factor features associated with objective variable, the method of step-by-step rejection/inclusion of explanatory variables (stepwise) was certified. Triglyceride level ≥1.7 mmol/L was statistically associated with the risk of high HOMA-2 IR [OR = 5.730 (95%CI 1.280–25.60) \( p = 0.0223 \)] (Figure 6).

According parameters: HOMA-1 IR, HOMA-2 IR, %B and %S a dendrogram was constructed using Ward’s hierarchical method, which clearly showed four clusters (Figure 7).
classified the resulting subgroups so that cluster 1 had the worst values of the studied parameters and cluster 4 had the best values (Table 1). By substituting anthropometric and lipid metabolic values into subgroups, a multiple comparison was made between the 4 samples. The Kruskal-Wallis one-way analysis-of-variance-by-ranks H-test of BMI (H = 4.1, p = 0.248) and WC (H = 3.9, p = 0.272) non-significant difference were obtained. It was found, that HOMA-1 IR was much higher in cluster 1 (6.32 ± 0.66) than in cluster 4 (2.19 ± 0.13). HOMA-2 IR was also much higher in cluster 1 (3.80 ± 0.34) than in cluster 4 (1.31 ± 0.06). By analysis of variance using Scheffe’s multiple comparison method, a statistically significant difference was obtained between the laboratory parameters among the subgroups: HOMA-1 IR (p < 0.001), glucose (p < 0.001), insulin (p < 0.001), HOMA-2 IR (p < 0.001), %B (p < 0.001), %S (p < 0.001), TG (p = 0.005) and VLDL-C (p = 0.002). No statistically significant difference was found between other parameters of lipid metabolism: TC (p = 0.292), HDL-C (p = 0.213), LDL-C (p = 0.441), AC (p = 0.187) (Table 1).

**Discussion**

In our study, there was a predominance of boys over girls, which confirms the results of a meta-analysis, where according to the IDF criteria MetS was more prevalent in males (3.46%; 95% CI 2.69, 4.23, I2 = 97.6%) than females (2.99%; 95% CI 2.34, 3.65, I2 = 95.6%) (2). The median of HOMA-1 IR was
FIGURE 7
Ward’s hierarchical dendrogram.
significantly higher than HOMA-2 IR, so by determining only the HOMA-1 IR we may lose some patients, on the other hand determining insulin resistance with HOMA-2 IR may be a more sensitive method and represent data from the current population. However, further studies of the MetS with a control group of healthy children are necessary. In a recent study, it was shown that HOMA-2 IR is more predictive than HOMA-1 IR for the progression to diabetes in pre-diabetes group, but there was no statistically significant difference in the non-diabetic group (16). An interesting phenomenon was that although males are more likely to suffer from MetS than females, they were found to have a higher insulin sensitivity. Further research is needed on gender differences in beta cell activity and insulin sensitivity in a larger sample of patients. Since there are no national reference values for HOMA-2 IR, we proposed level >2.26 to be the cut-off value for children and adolescents with MetS. However, the creation of national HOMA-2 IR percentile tables based on the age of child is important. It may be justifiable to consider that HOMA-2 IR was found to be even more sensitive for gender differences than HOMA-1 IR. It was also shown that TG level ≥1.7 mmol/L as one of the criteria of MetS was statistically associated with the risk of HOMA-2 IR >2.26. We found the correlations between HOMA-1 IR, HOMA-2 IR, %B and %S with TG and VLDL-C and a significant negative correlation between %B and HDL-C in childrens and adolescents with MetS. Similar results have been shown previously demonstrated by Shuang Zheng et al., in adults without diabetes (17). Surprisingly, by constructing a logistic model of regression, we found that the risk of high HOMA-2 IR decreases with age. This phenomenon requires further research.

Clustering of MetS in children and adults based on HOMA-1 IR, HOMA-2 IR, %B and %S on the basis of one pathological mechanism – insulin resistance, we conducted for the first time. Thus, we identified four subgroups at risk for the development of MetS complications. We recommend paying special attention to the first two subgroups, because they have poorer values not only of key indicators, but also to lipid metabolism. The first and the second clusters have the highest level of %B and the lowest level of %S. An abnormality in beta cell activity and loss of tissue sensitivity to insulin with decreased activity in peripheral tissues (mainly such as muscle, adipose and liver tissue) caused a number of metabolic and related diseases (18). A number of studies have shown that insulin resistance has been associated with a risk of developing asthma due to decrease glucose utilization and induction of abnormal fat metabolism in the skeletal muscles of respiratory system (19). A high prevalence of asthma was also found in children with high serum TG level (20). The elevated insulin can lead to increased androgen production, which can impair insulin sensitivity and lead to the metabolic imbalance that characterizes polycystic ovarian syndrome (PCOS) (21).

### TABLE 1. Characteristics of the studied patients by subgroups (clusters).

| Variables          | Cluster 1 (n = 20) | Cluster 2 (n = 22) | Cluster 3 (n = 18) | Cluster 4 (n = 15) | p       |
|--------------------|--------------------|--------------------|--------------------|--------------------|---------|
| Age (y)            | 14 ± 0.36 (13.15)  | 15 ± 0.49 (14.16)  | 15 ± 0.52 (14.16)  | 15 ± 0.70 (11.15)  | 0.086   |
| BMI (kg/m²)        | 30.01 ± 1.25 (27.73;33.96) | 27.89 ± 0.83 (26.36;30.82) | 29.07 ± 1.07 (27.38;32.61) | 27.43 ± 1.18 (24.68;30.56) | 0.248   |
| WC (cm)            | 94 ± 2.36 (86.100) | 90 ± 1.78 (88.92)  | 93.5 ± 2.03 (89.96) | 90 ± 2.03 (86.92)  | 0.272   |

*Mean ± SD (Min–Max)*

| Variables          | Cluster 1 (n = 20) | Cluster 2 (n = 22) | Cluster 3 (n = 18) | Cluster 4 (n = 15) | p     |
|--------------------|--------------------|--------------------|--------------------|--------------------|-------|
| %B                 | 329 ± 14.38 (178.9 ± 235.6) | 212.1 ± 3.77 (249.6 ± 483.1) | 146.6 ± 3.38 (121.3 ± 169.7) | 127.6 ± 4.99 (87.5 ± 121.1) | <0.001 |
| %S                 | 32.49 ± 3.76 (21.5 ± 52)   | 35.64 ± 1.99 (14.9 ± 82.5) | 50.39 ± 1.87 (35.5 ± 64.8)  | 78.99 ± 4.32 (57.5 ± 121.1)  | <0.001 |
| TC (mmol/L)        | 3.97 ± 0.28 (2.83 ± 5.36)  | 3.73 ± 0.28 (3.06 ± 4.91)  | 3.62 ± 0.23 (2.42 ± 4.9)    | 4.29 ± 0.37 (2.1 ± 5.93)     | 0.028  |
| TG (mmol/L)        | 2.24 ± 0.39 (1.78 ± 3.5)   | 1.52 ± 0.29 (0.76 ± 6.16)  | 1.05 ± 0.14 (0.58 ± 1.95)   | 0.85 ± 0.09 (0.32 ± 1.21)    | 0.005  |
| HDL-C (mmol/L)     | 1.03 ± 0.04 (0.7 ± 1.66)   | 1.16 ± 0.09 (0.77 ± 1.33)  | 1.18 ± 0.08 (0.8 ± 1.9)     | 1.26 ± 0.09 (0.77 ± 1.77)    | 0.213  |
| LDL-C (mmol/L)     | 2.67 ± 0.16 (1.7 ± 3.96)   | 2.29 ± 0.26 (2.02 ± 3.71)  | 2.42 ± 0.21 (1.42 ± 3.72)   | 2.66 ± 0.52 (0.58 ± 4.1)     | 0.441  |
| VLDL-C (mmol/L)    | 0.82 ± 0.15 (0.34 ± 0.65)  | 0.45 ± 0.05 (0.35 ± 1.9)   | 0.37 ± 0.04 (0.27 ± 0.69)   | 0.34 ± 0.04 (0.15 ± 0.51)    | 0.002  |
| AC (IU)            | 3.09 ± 0.31 (1.45 ± 3.6)   | 2.26 ± 0.32 (1.62 ± 5.1)   | 2.31 ± 0.35 (1.24 ± 4.99)   | 2.15 ± 0.37 (0.35 ± 3.71)    | 0.187  |

*pKruskal-Wallis rank one-way analysis on ranks with multiple comparisons for 4 samples (clusters)
dAnalysis of variance. Scheffe’s method of multiple comparisons for 4 samples (clusters)
comorbidities related to metabolic syndrome such as bronchial asthma, polycystic ovarian syndrome, behavioral disorders, obstructive sleep apnea and non-alcoholic fatty liver disease (23). So, the screening for these conditions should be recommended. All children of all subgroups we recommend to do HOMA-1 IR and HOMA-2 IR test with assessing $\beta$-cell function every 6 months.

Conclusion

1. Median HOMA-1 IR was significantly higher than median HOMA-2 IR and that’s why determinations insulin resistance only by HOMA-1 IR can ignore most patients.
2. We proposed HOMA-2 IR level >2.26 to be the cut-off value for children and adolescents with MetS.
3. Males had lower HOMA-2 IR and higher insulin sensitivity compared with females. No gender differences were found when comparing the HOMA-1 IR.
4. HOMA-1 IR, HOMA-2 IR, %B and %S were correlated with lipid metabolism parameters: TG and VLDL-C and negative correlated between %B and HDL-C in children and adolescents with MetS. The risk of getting a high TG result in the blood analysis in children with MetS was significantly associated with the HOMA-2 IR >2.26
5. Identification of four subgroups at risk of MetS complications in children and adolescents is an effective tool in predicting the development of MetS in children and adolescents from mild to more severe and will help pediatricians to individualize their approach to the treatment of MetS.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by Commission on Bioethical Expertise and Research Ethics at the Bogomolets National Medical University. Written informed consent to participate in this study was provided by the participant’s legal guardian/next of kin.

Author contributions

MHA: collected and analyzed the data, wrote the article; GVG: analyzed the data; AVC: helped design the study and revise article; IOM: conducted a critical revision of the manuscript. All authors have read and approved the manuscript. All authors contributed to the article and approved the submitted version.

Funding

We would like to thanks the grant support that was provided by O.O. Bogomolets National Medical University. This scientific work is part of the research work Grant No. 0118U000151 of the Department of Pediatrics 4.

Acknowledgments

We thank the head of Cardiology Department of Children’s Clinical Hospital No.6 Kukhta Natalia for access to examine the children. We would also like to thank the Armed Forces of Ukraine for providing security to perform this work. This work has become possible only because resilience and courage of the Ukrainian Army.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Reisinger C, Nkeh-Chungag BN, Fredriksen PM, Goswami N. The prevalence of pediatric metabolic syndrome—a critical look on the discrepancies between definitions and its clinical importance. Int J Obes. (2021) 45:12–24. doi: 10.1038/s41366-020-00713-1
2. Bitem ZW, Alemu A, Ayde EG, Tenaw Z, Alebel A, Worku T. Metabolic syndrome among children and adolescents in low and middle income countries: a systematic review and meta-analysis. *Diabetol Metab Syndr.* (2020) 12:e1. doi: 10.1186/s13098-020-00601-8

3. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, Arslanian S, et al. The metabolic syndrome in children and adolescents – an IDF consensus report. *Pediatr Diabetes.* (2007) 8(5):299–306. doi: 10.1111/j.1399-5448.2007.00271.x

4. Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel insights into the pathogenesis and management of the metabolic syndrome. *Pediatr Gastroenterol Hepatol Nutr.* (2020) 23(3):189–230. doi: 10.5223/pghn.2020.23.3.189

5. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. *Physiol Rev.* (2018) 98(4):2133–223. doi: 10.1152/physrev.00063.2017

6. Wallace TM, Levy JC, Matthews DR. Use and abuse of homa modeling. *Diabetes Care.* (2004) 27(6):1487–95. doi: 10.2337/diacare.27.6

7. Mukherjee N, Lin L, Contreras CJ, Templin AT. β-Cell death in diabetes: past discoveries, present understanding, and potential future advances. *Metabolites.* (2021) 11(11):796. doi: 10.3390/metabo11110796

8. Cerf ME. Beta cell physiological dynamics and dysfunctional transitions in response to islet inflammation in obesity and diabetes. *Metabolites.* (2020) 10(11):452. doi: 10.3390/metabo10110452

9. Ye B, Ondodera T, Scherer PE. Lipotoxicity and β cell maintenance in obesity and type 2 diabetes. *J Endocr Soc.* (2019) 3(3):617–31. doi: 10.1210/js.2018-00372

10. Tarlton J, Lightbody RJ, Patterson S, Graham A. Protection against glycolipotoxicity by high density lipoprotein in human PANC-1 hybrid 1B4 pancreatic beta cells: the role of miRNA. *Biologics.* (2021) 10(3):218. doi: 10.3390/biologics10030218

11. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*power 3.1: tests for correlation and regression analyses. *Behav Res Methods.* (2009) 41:1149–60. doi: 10.3758/BRM.41.4.1149

12. Varagiannis P, Magriples E, Rivas G, Vamvouka K, Nisianaki A, Papaefstathiou A, et al. Effects of three different family-based interventions in overweight and obese children: the “4 your family” randomized controlled trial. *Nutrients.* (2021) 13(2):341. doi: 10.3390/nu13020341

13. Pena-Hernandez C, Nugent K, Tuncel M. Twenty-four-hour ambulatory blood pressure monitoring. *J Prim Care Community Health.* (2020) 11:215033720940519. doi: 10.1177/215033720940519

14. Huang QF, Yang WY, Asayama K, Zhang ZY, Thijs L, Li Y, et al. Ambulatory blood pressure monitoring to diagnose and manage hypertension. *Hypertension (Dallas, Tex.: 1979).* (2021) 77(2):254–64. doi: 10.1161/HYPERTENSIONAHA.120.14591

15. Chairelli F, Mohan A. Early diagnosis of metabolic syndrome in children. *Lancet Child Adolesc Health.* (2017) 1(2):86–8. doi: 10.1016/s2352-4642(17)30043-3

16. Song YS, Hwang YC, Ahn HY, Park CY. Comparison of the usefulness of the updated homeostasis model assessment (HOMA2) with the original HOMA1 in the prediction of type 2 diabetes mellitus in Koreans. *Diabetes Metab J.* (2016) 40(4):318–26. doi: 10.4093/dmj.2016.40.4.318

17. Zheng S, Xu H, Zhou H, Ren X, Han T, Chen Y, et al. Associations of lipid profiles with insulin resistance and β cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation. *PLoS ONE.* (2017) 12(2):e0172221. doi: 10.1371/journal.pone.0172221

18. Rojas J, Bermudez V, Palmar J, Martinez MS, Ollivar LC, Nava M, et al. Pancreatic beta cell death: novel potential mechanisms in diabetes therapy. *J Diabetes Res.* (2018) 2018:1–19. doi: 10.1155/2018/9601801

19. Pite H, Aguilar L, Morello J, Monteiro E, Alves AC, Bourbon M, et al. Metabolic dysfunction and asthma: current perspectives. *J Asthma Allergy.* (2020) 13:237–47. doi: 10.2147/jaa.s208823

20. Ko SH, Jeong J, Baeg MK, Han KD, Kim HS, Yoon JS, et al. Lipid profiles in adolescents with and without asthma: korea national health and nutrition examination survey data. *Lipids Health Dis.* (2018) 17(1):158. doi: 10.1016/s1294-018-0807-4

21. Calcagno V, Verdaci E, Gena H, Magenes VC, Todisco CF, Tenuta E, et al. Polycystic ovary syndrome in insulin resistant adolescents with obesity: the role of nutrition therapy and food supplements as a strategy to protect fertility. *Nutrients.* (2021) 13:1848. doi: 10.3390/nu13061848

22. Michalek-Zrabkowska M, Macek P, Martynowicz H, Gac P, Mazur G, Gerezda M, et al. Obstructive sleep apnea as a risk factor of insulin resistance in nonobese adults. *Life (Basel, Switzerland).* (2021) 11(1):50. doi: 10.3390/ life11010050

23. Cuda SE, Censani M. Pediatric obesity algorithm: a practical approach to obesity diagnosis and management. *Front Pediatr.* (2019) 6:431. doi: 10.3389/fped.2018.00431